The DOI matches its Crossref record.
Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study
Abstract
In preclinical studies, LSD1 inhibitors derived from tranylcypromine were active in acute myeloid leukemia models, particularly in the MLL-translocated subtype. We now report the safety, PK and PD properties of ORY-1001 (a potent and selective inhibitor of LSD1) in a multicenter phase I study (EUDRACT nº 2013-002447-29). The primary objective was to assess safety and tolerability in relapsed or refractory acute leukemia (RR-AL). Secondary objectives were to a) characterize PK, b) to monitor a panel of surrogate PD markers for target engagement and c) assess clinical response. Patients ≥16yr with RR-AL, ECOG PS ≤2 and life expectancy >8wk were eligible. ORY-1001 was administered orally once daily in a 28 day cycle (5d ON/2d OFF x4wk). Plasma ORY-1001 levels were analyzed by HPLC-MS/MS. Blood leukocyte expression of candidate differentiation PD biomarkers was determined by qRT-PCR. Twenty-seven subjects (mean age 66.5, range 40-81; gender 19 M/8F) were recruited into the dose escalation phase (26 - RR-AML; 1 - RR-ALL). Mean time since initial diagnosis was 12.6 months and since last treatment was 2.1 months. Twenty patients completed cycle 1, 9 started cycle 2 with 3 completions and 3 started and completed cycle 3. The most frequent ADR was thrombocytopenia (7 events, 5 subjects). Twenty-two subjects experienced 32 SAEs of which two (Cohort 8 - 220 µg/m2/d) were considered possibly related to ORY-1001: grade 5 lobar pneumonia and grade 3 febrile neutropenia (in combination with grade 2 fatigue and grade 2 erythema multiforme). These were considered dose limiting toxicities. Consequently the recommended dose for the extension phase was established at 140 μg/m2/d. At the end of the dose escalation phase, 358 treatment emergent AEs were reported. The most frequent were asthenia (16 events, 12 subjects), febrile neutropenia (15 events, 13 subjects), constipation (12 events, 9 subjects) and peripheral oedema (11 events, 8 subjects). ORY-1001 plasma concentration increased with dose across cohorts. At 140 µg/m2/d (recommended dose) on d1 mean±SD Cmax was 13.1±7.2 and mean±SD AUC (0-24h) was 181.7±61.3pg.hr/mL. On d5 mean±SD Cmax was 42.2±27 and mean±SD AUC (0-24h) 723.3±341.5pg.hr/mL. PD biomarker response varied due to differences in disease genetics and circulating blast percentages. Nevertheless select biomarkers demonstrated time and dose dependent response profiles in individual patients. For example, PI16 (peptidase inhibitor 16; or CRISP-9) levels were induced in cohort 7 (140 µg/m2/d). Maximum PI16 induction was seen at 18hr on d1, pre-dose levels remained high on d5 and were sustained through the OFF period until pre-dose on d8. An extension cohort of 14 patients (mean age 57; range 30-78, gender 8M/6F) with specific RR-AML subtypes predicted to be more sensitive based upon preclinical studies, was also enrolled (AML MLL-translocated n=10; acute erythroleukemia/M6 n=4). At data cut-off (31 July 2016), 131 AEs and 27 SAEs have been reported. Eight SAEs were considered related to treatment, including a differentiation syndrome in two patients. PK and PD analyses are ongoing. For response assessment, 14 patients were evaluable. Objective responses were seen in 5/14 patients (36%): two patients with t(9;11) exhibited stable disease and three a partial response (one MLL after 3 cycles, and two M6). Importantly, there was evidence of morphologic blast differentiation in blood and/or BM in 9/14 patients (5 MLL and 4 M6). In summary, ORY-1001 at the recommended dose is well tolerated and promotes blast cell differentiation in 64% of patients. This, together with the partial responses observed, suggest that LSD1 inhibition may be a possible therapy for some AML patients. Disclosures: Somervaille: Novartis: Consultancy, Honoraria; Imago Biosciences: Consultancy. Pigneux:Agios: Consultancy, Honoraria; Sunesis: Consultancy, Honoraria. Recher:Celgene, Sunesis, Amgen, Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene, Sunesis, Amgen, Novartis, Chugai: Research Funding. Molinero:Oryzon Genomics: Employment, Equity Ownership. Mascaro:Oryzon Genomics: Employment. Maes:Oryzon Genomics: Employment, Equity Ownership.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“whilst several epigenetic therapies targeting the prototypical oncogene MYC through transcriptional repression generated much excitement, it is now clear that this is only transiently effective as cancer cells evolve multiple adaptive responses to retain MYC expression 184-186 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [186]
In the citing paper
“Preclinical modelling of resistance mechanisms has shown that resistance to these therapies largely emerge through cellular reprogramming and transcriptional plasticity 184-186 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [186]
Citations
Cited by
Sorted by citations
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
LSD1/KDM1A inhibitors in clinical trials: advances and prospects
Fang, Y., Liao, G., & Yu, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0811-9 · Cited by 453
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 427
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia
Maes, T., Mascaró, C., Tirapu, I., Estiarte, A., Ciceri, F., Lunardi, S., Guibourt, N., Perdones, A., Lufino, M. M., Somervaille, T. C. P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.002 · Cited by 345
Self-citationTreatment of Relapsed/Refractory Acute Myeloid Leukemia
Bose, P., Vachhani, P. J., & Cortes, J. E. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0456-2 · Cited by 241
Maiqués-Díaz, A., Spencer, G. J., Lynch, J. T., Ciceri, F., Williams, E. L., Amaral, F. M. R., Wiseman, D. H., Harris, W. J., Li, Y., Sahoo, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.012 · Cited by 208
“OG86 Induces a Myeloid Differentiation Program in MLL-Translocated AML Cells Treatment of patients with MLL-translocated AML with ORY1001, a tranylcypromine-derivative inhibitor of LSD1 (Maes et al., 2015), induces differentiation of blast cells in blood and bone marrow (Somervaille et al., 2016); and the related pote…”
BackgroundInfluentialSelf-citationRecent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Nepali, K., & Liou, J. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00721-x · Cited by 187
Clinical advances in targeting epigenetics for cancer therapy
Feng, S., & Carvalho, D. D. D. (2021) · FEBS Journal · doi:10.1111/febs.15750 · Cited by 109
van Gils, N., Denkers, F., & Smit, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659253 · Cited by 108
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718816698 · Cited by 88
Bauer, T. M., Besse, B., Martínez‐Martí, A., Trigo, J. M., Moreno, V., Garrido, P., Ferron‐Brady, G., Wu, Y., Park, J., Collingwood, T. S., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.021 · Cited by 91
Li, Z., Ding, L., Li, Z., Wang, Z., Suo, F., Shen, D., Zhao, T., Sun, X., Wang, J., Liu, Y., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.01.001 · Cited by 83
Differentiation therapy of myeloid leukemia: four decades of development
Madan, V., & Koeffler, H. P. (2020) · Haematologica · doi:10.3324/haematol.2020.262121 · Cited by 72
LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma
Leiendecker, L., Jung, P. S., Kręcioch, I., Neumann, T., Schleiffer, A., Mechtler, K., Wiesner, T., & Obenauf, A. C. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012525 · Cited by 65
“Putting our findings in MCC in the broader context of studies investigating LSD1i treatment in other cancers, such as AMLs (Schenk et al, 2012; Somervaille et al, 2016; Fang et al, 2019; Cai et al, 2020), SCLC (Mohammad et al, 2015; Augert et al, 2019), prostate cancer (Sehrawat et al, 2018), and…”
MethodCuyàs, E., Gumuzio, J., Verdura, S., Brunet, J., Bosch‐Barrera, J., Martı́n-Castillo, B., Alarcón, T., Encinar, J. A., Martín, Á. G., & Menéndez, J. A. (2020) · Aging · doi:10.18632/aging.102887 · Cited by 61
“Based on these findings, the Phase IIa ALICE study is currently ongoing in elderly patients with AML not eligible for intensive chemotherapy to combine iadademstat with standard of care azacytidine (https://www.clinicaltrialsregister.eu/ctrsearch/trial/2018-000482-36/ES).”
BackgroundInfluential20 years of histone lysine demethylases: From discovery to the clinic and beyond
Gray, Z. H., Honer, M. A., Ghatalia, P., Shi, Y., & Whetstine, J. R. (2025) · Cell · doi:10.1016/j.cell.2025.02.023 · Cited by 59
Mould, D. P., Alli, C., Bremberg, U., Cartic, S., Jordan, A. M., Geitmann, M., Maiqués-Díaz, A., McGonagle, A. E., Somervaille, T. C. P., Spencer, G. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00462 · Cited by 48
Self-citationHollebecque, A., Salvagni, S., Plummer, R., Isambert, N., Niccoli, P., Capdevila, J., Curigliano, G., Moreno, V., Martín-Romano, P., Baudin, É., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2380 · Cited by 48
Ma, L., Wang, H., You, Y., Ma, C.-Y., Liu, Y., Yang, F., Zheng, Y., & Liu, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.006 · Cited by 43
Deb, G., Wingelhofer, B., Amaral, F. M. R., Maiqués-Díaz, A., Chadwick, J. A., Spencer, G. J., Williams, E. L., Leong, H. S., Maes, T., & Somervaille, T. C. P. (2019) · Leukemia · doi:10.1038/s41375-019-0659-6 · Cited by 38
“THP1 AML cells were selected because they exhibit a t(9;11) MLL gene rearrangement and respond to LSD1 inhibition in a similar manner to primary patient MLL-translocated AML cells, with differentiation and loss of clonogenic activity [8, 9].”
BackgroundSelf-citationLSD1 in drug discovery: From biological function to clinical application
Liu, H., Zhou, Y., Chen, H., Wu, J., Ji, S., Shen, L., Wang, S., Liu, H., Liu, Y., Dai, X., et al. (2023) · Medicinal Research Reviews · doi:10.1002/med.22000 · Cited by 41
“142,143 In AML, ORY ‐ 1001 causes H3K4me2 accumulation on the promoter of LSD1 target genes.”
BackgroundSaloura, V., Vougiouklakis, T., Sievers, C. M., Burkitt, K., Nakamura, Y., Hager, G. L., & Waes, C. V. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.04.014 · Cited by 40
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy
Shen, L., Wang, B., Wang, S., Ji, S., Fu, M., Wang, S.-W., Hou, W., Dai, X., & Liu, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02133 · Cited by 39
Li, Z., Qin, T., Li, Z., Zhao, X., Zhang, X., Zhao, T., Yang, N., Miao, J., Ma, J., & Zhang, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113778 · Cited by 34
MacLean, M. R., Walker, O. L., Arun, R. P., Fernando, W., & Marcato, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074102 · Cited by 32
Montesinos, P., Bergua, J., Infante, J. B., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03820-w · Cited by 27
Self-citationLi, Z., Ma, J., Liu, G., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111989 · Cited by 26
Novel epigenetic therapies in hematological malignancies: Current status and beyond
Gallipoli, P., & Huntly, B. J. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.005 · Cited by 25
“Furthermore, there was evidence of blast differentiation and partial responses in almost 40% of evaluable patients, suggesting that further investigations are warranted[137].”
BackgroundHerrlinger, E., Hau, M., Redhaber, D. M., Greve, G., Willmann, D., Steimle, S., Müller, M., Lübbert, M., Miething, C., Schüle, R., et al. (2020) · ChemBioChem · doi:10.1002/cbic.202000138 · Cited by 24
What potential is there for LSD1 inhibitors to reach approval for AML?
Pandey, M. R., & Wang, E. S. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1694001 · Cited by 22
“ORY, in patients enriched for AML characterized by MLL translocations and M6 morphology [30].”
BackgroundBiological and therapeutic role of LSD1 in Alzheimer’s diseases
Li, Y., Zhao, Y., Li, X., Zhai, L., Zheng, H., Yan, Y., Fu, Q., Ma, J., Fu, H., Zhang, Z., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1020556 · Cited by 25
“…of ring cleavage of TCP to form FAD adducts needs to be further studied, which is important to design potent and specific inhibitors without disrupting the interaction of LSD1 with cofactors like GFI1B, thereby reducing blood toxicity (Maiques-Diaz and Somervaille, 2016; Matsuda et al., 2019).”
BackgroundMould, D. P., Bremberg, U., Jordan, A. M., Geitmann, M., Maiqués-Díaz, A., McGonagle, A. E., Small, H. F., Somervaille, T. C. P., & Ogilvie, D. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.018 · Cited by 19
Self-citationYang, F., Xu, X.-L., Hu, T., Liu, J., Zhou, J.-Z., Ma, L., & Liu, H. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01527 · Cited by 21
Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia
Wingelhofer, B., & Somervaille, T. C. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00850 · Cited by 18
Self-citationThe evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia
Gonzalez‐Lugo, J. D., Chakraborty, S., Verma, A., & Shastri, A. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.12.003 · Cited by 11
Pharmacoepigenetics of LSD1 Inhibitors in Cancer
Yu, B., & Liu, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00014-0 · Cited by 9
Discovery of Pyrrolo[2,3‑ c ]pyridines as Potent and Reversible LSD1 Inhibitors
Zheng, C., Rej, R. K., Wang, M., Huang, L., Fernández‐Salas, E., Yang, C., & Wang, S. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00292 · Cited by 6
Hong, Y., Wang, Y., Hao, Z., Zhang, X., Si, Y., Lin, G., Zhang, S., Niu, M., Yang, X., & Zhang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1510319 · Cited by 3
Targeted therapy in KMT2Ar AML
Zhang, Y., Yang, Y.-K., Du, Y., Tang, Y., & Gong, Y. (2025) · Hematology · doi:10.1080/16078454.2025.2599585 · Cited by 1
Inhibitors targeting epigenetic modifications in cancer
Baghel, V. S., Shinde, S., Sinha, V., Dixit, V., Tiwari, A. K., Saxena, S., Vishvakarma, N. K., Shukla, D., & Bhatt, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99521-4.00007-6 · Cited by 1
Differentiating Acute Myeloid Leukemia Stem Cells/Blasts
Schembri-Wismayer, P., Gatt, L., & Cassar, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00014-7
The Histone‐Lysine N‐Methyltransferase (KMT2) Family in Health and Disease
Wang, Q., Bo, Z., Zhang, Y., Chen, Y., Wang, Z., Tong, S., Xu, A., Zhang, G., & Liu, Y. (2026) · MedComm · doi:10.1002/mco2.70728
Wang, Y., Zhou, W.-W., Jia, G., Huang, X., & Song, Z.-Y. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02708-3
Metadata
- Authors
- Somervaille, T., Salamero, O., Montesinos, P., Willekens, C., Perez Simon, J. A., Pigneux, A., Recher, C., Popat, R., Molinero, C., Mascaro, C., Maes, T., & Bosch, F.
- Affiliations
- The Christie NHS Foundation Trust (GB)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Institut Gustave Roussy (FR)
- Hospital Universitario Virgen del Rocío, Seville, Spain
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France
- University College London Hospitals NHS Foundation Trust (GB)
- Oryzon Genomics, Barcelona, Spain
- Oryzon Genomics (Spain) (ES)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-12-02
- Volume
- 128
- Issue
- 22
- Pages
- 4060-4060
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2726227284
- Cited by
- 46
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 1 · 2021: 4 · 2020: 7 · 2019: 12 · 2018: 3 · 2017: 4
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute leukemia, relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, pharmacokinetics, pharmacodynamics, target engagement biomarkers, dose escalation, thrombocytopenia, pneumonia, febrile neutropenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
